Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
01833 PA GOODDOCTOR
RTNominal down97.200 -2.700 (-2.703%)
Research Report

27/01/2021 17:19

{I-bank focus}MacQ cuts PA Good Doctor (01833) to HK$110

[ET Net News Agency, 27 January 2021] Macquarie Research trimmed its target price for
PingAn Healthcare and Tech (PAGD) (01833) to HK$110 from HK$152 and maintained its "buy"
rating.
PAGD is expected to release annual 2020 results on 2 February. The research house
believes the focus will be around membership growth, the progress of the online hospital
establishment, and the potential integration of online and offline traffic.
Macquarie expects revenue growth to rebound with a slight margin improvement. It
estimated 31% revenue growth in 2H, improving from 21% in 1H, which is attributable to
continued online medical service (OMS) growth of 65% plus the recovery of consumer
healthcare growth at 25% due to easing of the COVID-19 lockdown in 2H. Meanwhile, it
expects the adjusted OPM to improve 6.3ppts in 2H.
The research house revised its 2020/21/22 EPS estimates from Rmb-0.37/-0.10/0.65 to
Rmb-0.88/-1.05/-0.71 due to expected S&M spending on new initiatives. (KL)

Remark: Real time quote last updated: 12/04/2021 13:08
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2021 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.